Yapan Bio Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 20-12-2024
- Paid Up Capital ₹ 3.60 M
as on 20-12-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.53 Cr
as on 20-12-2024
- Satisfied Charges ₹ 6.25 Cr
as on 20-12-2024
- Revenue -30.79%
(FY 2023)
- Profit -98.49%
(FY 2023)
- Ebitda -66.62%
(FY 2023)
- Net Worth -1.68%
(FY 2023)
- Total Assets 4.12%
(FY 2023)
About Yapan Bio
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 3.60 M.
The company currently has active open charges totaling ₹10.53 Cr. The company has closed loans amounting to ₹6.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Atin Tomar, Nirav Desai, and Debasish Chakravorty serve as directors at the Company.
- CIN/LLPIN
U74110TG2019PTC136037
- Company No.
136037
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Oct 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Yapan Bio?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atin Tomar  | Director | 11-Oct-2019 | Current |
| Nirav Desai | Director | 11-Oct-2019 | Current |
| Debasish Chakravorty | Nominee Director | 01-Feb-2024 | Current |
Financial Performance of Yapan Bio.
Yapan Bio Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 30.79% decrease. The company also saw a substantial fall in profitability, with a 98.49% decrease in profit. The company's net worth dipped by a decrease of 1.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Yapan Bio?
In 2023, Yapan Bio had a public holding of 33.33%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 29 Jul 2021 | ₹7.99 M | Open |
Hdfc Bank Limited Creation Date: 19 Jul 2021 | ₹7.31 M | Open |
Citi Bank N.A. Creation Date: 07 Jul 2021 | ₹2.00 Cr | Open |
How Many Employees Work at Yapan Bio?
Yapan Bio has a workforce of 49 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Yapan Bio, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Yapan Bio's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
